Discovery of Dual VEGFR-2 and Tubulin Inhibitors with in Vivo Efficacy
ACS Medicinal Chemistry Letters2010Vol. 1(9), pp. 488–492
Citations Over Time
Eugene L. Piatnitski Chekler, Alexander S. Kiselyov, Xiaohu Ouyang, Xiaoling Chen, Vatee Pattaropong, Ying Wang, M. Carolina Tuma, Jacqueline Doody
Abstract
In an effort to develop potent, orally bioavailable compounds for the treatment of neoplastic diseases, we developed a class of dual VEGFR-2 kinase and tubulin inhibitors. Targeting the VEGFR receptor kinase and tubulin structure allows for inhibition of both tumor cells and tumor vasculature. Previously, a combination of two compounds, a VEGF receptor tyrosine kinase inhibitor and tubulin agent, was demonstrated to produce an enhanced antitumor response in animal studies. We have reaffirmed their results, with the added benefit that both activities are found in one compound.
Related Papers
- → α-tubulin tail modifications regulate microtubule stability through selective effector recruitment, not changes in intrinsic polymer dynamics(2021)82 cited
- → Generation of Differentially Polyglutamylated Microtubules(2011)12 cited
- Effect of microtubule-associated proteins on the interaction of vincristine with microtubules and tubulin.(1979)
- → Factors implicated in determining the structure of zinc tubulin‐sheets: Lateral tubulin–tubulin interaction is promoted by the presence of zinc(1981)12 cited